ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: TH-PO1049

Time-Updated Systolic Blood Pressure and Progression of CKD in Patients with Glomerulonephritis

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Kim, Hyung Woo, College of Medicine, Institute of Kidney Disease Research, Yonsei University, Seoul, Korea (the Republic of)
  • Kim, Seonghun, College of Medicine, Severance Biomedical Science Institute, Brain Korea 21 PLUS, Yonsei University, Seoul, Korea (the Republic of)
  • Nam, Boyoung, College of Medicine, Severance Biomedical Science Institute, Brain Korea 21 PLUS, Yonsei University, Seoul, Korea (the Republic of)
  • Park, Jimin, College of Medicine, Severance Biomedical Science Institute, Brain Korea 21 PLUS, Yonsei University, Seoul, Korea (the Republic of)
  • Park, Jung Tak, College of Medicine, Institute of Kidney Disease Research, Yonsei University, Seoul, Korea (the Republic of)
  • Han, Seung Hyeok, College of Medicine, Institute of Kidney Disease Research, Yonsei University, Seoul, Korea (the Republic of)
  • Kang, Shin-Wook, College of Medicine, Institute of Kidney Disease Research, Yonsei University, Seoul, Korea (the Republic of)
  • Yoo, Tae-Hyun, College of Medicine, Institute of Kidney Disease Research, Yonsei University, Seoul, Korea (the Republic of)
Background

Many guidelines on optimal target of blood pressure in chronic kidney disease are largely based on studies in diabetic and hypertensive patients. However, there is lack of evidence that this blood pressure goal can also be applied to patients with glomerular diseases. The aim of this study was to clarify the longitudinal association between blood pressure and CKD progression in patients with glomerulonephritis.

Methods

We studied 1,016 biopsy-proven patients who were diagnosed with primary glomerular diseases such as IgA nephropathy (n=756 [74.4%]), membranous glomerulonephritis (n=144 [14.2%]), and focal segmental glomerulosclerosis (n=116 [11.4%]) from 2005 to 2017. The main exposure of interest was baseline and time-updated systolic blood pressure (SBP). The primary outcome was a composite of a ≥50% decrease in eGFR from baseline or end-stage kidney disease. We used time-varying cox model and marginal structural model for time-updated SBP.

Results

During 1,607 person-years follow up, the primary outcome occurred in 658 (64.8%) patients. The mean age was 43.6±14.7 years and baseline eGFR was 90.4±28.0 ml/min/1.73 m2. 665 (65.5%) patients had the history of previous hypertension. Using time-varying cox model, compared with SBP of 120 to 129 mmHg, the hazard ratios for the primary outcome were 1.01 (95% CI, 0.84 to 1.22), 1.11 (95% CI, 0.88 to 1.40), 1.36 (95% CI, 1.04 to 1.78), respectively. The marginal structural model also showed consistent results. The corresponding HRs for the noted SBP categories were 1.04 (95% CI, 0.87 to 1.24; p=0.68), 1.14 (95% CI, 0.92 to 1.41; p=0.24), 1.43 (95% CI, 1.08 to 1.89 p=0.01), respectively. This association was consistent regardless of subgroups by age (<60 vs. ≥60), gender, previous hypertension, baseline eGFR (≥45 vs. <45), and proteinuria (<1g vs. ≥1g).

Conclusion

Among patients with glomerular diseases, SBP >140 mmHg was significantly associated with higher risk of CKD progression.